Emerging Neuropeptide Targets in Inflammation: NPY and VIP

Overview

Journal Am J Physiol Gastrointest Liver Physiol

Publisher American Physiological Society

Specialties Gastroenterology
Physiology

Date 2013 Mar 30

PMID 23538492

Citations 65

Authors

Bindu Chandrasekharan

Behtash Ghazi Nezami

Shanthi Srinivasan

Affiliations

Soon will be listed here.

Abstract

The enteric nervous system (ENS), referred to as the "second brain," comprises a vast number of neurons that form an elegant network throughout the gastrointestinal tract. Neuropeptides produced by the ENS play a crucial role in the regulation of inflammatory processes via cross talk with the enteric immune system. In addition, neuropeptides have paracrine effects on epithelial secretion, thus regulating epithelial barrier functions and thereby susceptibility to inflammation. Ultimately the inflammatory response damages the enteric neurons themselves, resulting in deregulations in circuitry and gut motility. In this review, we have emphasized the concept of neurogenic inflammation and the interaction between the enteric immune system and enteric nervous system, focusing on neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP). The alterations in the expression of NPY and VIP in inflammation and their significant roles in immunomodulation are discussed. We highlight the mechanism of action of these neuropeptides on immune cells, focusing on the key receptors as well as the intracellular signaling pathways that are activated to regulate the release of cytokines. In addition, we also examine the direct and indirect mechanisms of neuropeptide regulation of epithelial tight junctions and permeability, which are a crucial determinant of susceptibility to inflammation. Finally, we also discuss the potential of emerging neuropeptide-based therapies that utilize peptide agonists, antagonists, siRNA, oligonucleotides, and lentiviral vectors.

Citing Articles

Investigation of the Immunomodulatory and Neuroprotective Properties of Oil in Experimental Systemic and Neuroinflammation.

Mihaylova A, Doncheva N, Vlasheva M, Katsarova M, Gardjeva P, Dimitrova S Int J Mol Sci. 2025; 26(5).

PMID: 40076857 PMC: 11900984. DOI: 10.3390/ijms26052235.

Recent advances in the role of neuroregulation in skin wound healing.

Al Mamun A, Shao C, Geng P, Wang S, Xiao J Burns Trauma. 2025; 13:tkae072.

PMID: 39872039 PMC: 11770601. DOI: 10.1093/burnst/tkae072.

The effect of nerve cells on the intestinal barrier function and the influence of human milk oligosaccharides (hMOs) on the intestinal neuro-epithelial crosstalk.

Chen X, Gasaly N, Tang X, Walvoort M, de Vos P Curr Res Food Sci. 2024; 9:100851.

PMID: 39314222 PMC: 11417580. DOI: 10.1016/j.crfs.2024.100851.

Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling.

Castorina A, Scheller J, Keay K, Marzagalli R, Rose-John S, Campbell I Int J Mol Sci. 2024; 25(17).

PMID: 39273398 PMC: 11395455. DOI: 10.3390/ijms25179453.

Alterations of pleiotropic neuropeptide-receptor gene couples in Cetacea.

Valente R, Cordeiro M, Pinto B, Machado A, Alves F, Sousa-Pinto I BMC Biol. 2024; 22(1):186.

PMID: 39218857 PMC: 11367936. DOI: 10.1186/s12915-024-01984-0.

References

Rozengurt E . Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J Cell Physiol. 1999; 177(4):507-17. DOI: 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K. View

Huang M, Miller A, Wang W, Kong Y, Paul S, Goetzl E . Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2). J Immunol. 2006; 176(11):6640-6. PMC: 1551935. DOI: 10.4049/jimmunol.176.11.6640. View

Teixeira L, Sousa D, Nunes A, Sousa M, Herzog H, Lamghari M . NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J Cell Biochem. 2009; 107(5):908-16. DOI: 10.1002/jcb.22194. View

Nijhuis L, Olivier B, de Jonge W . Neurogenic regulation of dendritic cells in the intestine. Biochem Pharmacol. 2010; 80(12):2002-8. DOI: 10.1016/j.bcp.2010.06.034. View

Lu J, Zheng M, Yan J, Chen Y, Pan J . Effects of vasoactive intestinal peptide on phenotypic and functional maturation of dendritic cells. Int Immunopharmacol. 2008; 8(10):1449-54. DOI: 10.1016/j.intimp.2008.06.002. View

Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J . Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann N Y Acad Sci. 2006; 1070:129-34. DOI: 10.1196/annals.1317.001. View

Jonsson M, Norrgard O, Forsgren S . Epithelial expression of vasoactive intestinal peptide in ulcerative colitis: down-regulation in markedly inflamed colon. Dig Dis Sci. 2011; 57(2):303-10. DOI: 10.1007/s10620-011-1985-3. View

Neurath M, Becker C, Barbulescu K . Role of NF-kappaB in immune and inflammatory responses in the gut. Gut. 1998; 43(6):856-60. PMC: 1727350. DOI: 10.1136/gut.43.6.856. View

Baeuerle P, Henkel T . Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12:141-79. DOI: 10.1146/annurev.iy.12.040194.001041. View

10.

Duffy L, Zielezny M, Riepenhoff-Talty M, Byers T, Marshall J, Weiser M . Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease. Dig Dis Sci. 1989; 34(10):1528-35. DOI: 10.1007/BF01537105. View

11.

Su L, Shen L, Clayburgh D, Nalle S, Sullivan E, Meddings J . Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2008; 136(2):551-63. PMC: 2712351. DOI: 10.1053/j.gastro.2008.10.081. View

12.

Vasina V, Barbara G, Talamonti L, Stanghellini V, Corinaldesi R, Tonini M . Enteric neuroplasticity evoked by inflammation. Auton Neurosci. 2006; 126-127:264-72. DOI: 10.1016/j.autneu.2006.02.025. View

13.

Delgado M, Leceta J, Ganea D . Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol. 2003; 73(1):155-64. DOI: 10.1189/jlb.0702372. View

14.

Saksena S, Tyagi S, Goyal S, Gill R, Alrefai W, Ramaswamy K . Stimulation of apical Cl⁻/HCO₃⁻(OH⁻) exchanger, SLC26A3 by neuropeptide Y is lipid raft dependent. Am J Physiol Gastrointest Liver Physiol. 2010; 299(6):G1334-43. PMC: 3006247. DOI: 10.1152/ajpgi.00039.2010. View

15.

Grinninger C, Wang W, Oskoui K, Voice J, Goetzl E . A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. J Biol Chem. 2004; 279(39):40259-62. DOI: 10.1074/jbc.C400332200. View

16.

Saurer T, Ijames S, Lysle D . Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity. J Neuroimmunol. 2006; 177(1-2):18-26. DOI: 10.1016/j.jneuroim.2006.05.002. View

17.

Sun J, Ramnath R, Bhatia M . Neuropeptide substance P upregulates chemokine and chemokine receptor expression in primary mouse neutrophils. Am J Physiol Cell Physiol. 2007; 293(2):C696-704. DOI: 10.1152/ajpcell.00060.2007. View

18.

Wheway J, Mackay C, Newton R, Sainsbury A, Boey D, Herzog H . A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med. 2005; 202(11):1527-38. PMC: 2213323. DOI: 10.1084/jem.20051971. View

19.

Dimitrijevic M, Stanojevic S, Micic S, Vujic V, Kovacevic-Jovanovic V, Mitic K . Neuropeptide Y (NPY) modulates oxidative burst and nitric oxide production in carrageenan-elicited granulocytes from rat air pouch. Peptides. 2006; 27(12):3208-15. DOI: 10.1016/j.peptides.2006.08.018. View

20.

Medina S, Del Rio M, Hernanz A, de la Fuente M . Age-related changes in the neuropeptide Y effects on murine lymphoproliferation and interleukin-2 production. Peptides. 2000; 21(9):1403-9. DOI: 10.1016/s0196-9781(00)00284-9. View